Pacific Biosciences of California (PACB) Competitors $1.58 +0.09 (+6.04%) Closing price 07/3/2025 03:57 PM EasternExtended Trading$1.58 0.00 (-0.06%) As of 07/3/2025 04:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PACB vs. TXG, HBIO, TMO, A, MTD, WAT, ILMN, TECH, CRL, and BIOShould you be buying Pacific Biosciences of California stock or one of its competitors? The main competitors of Pacific Biosciences of California include 10x Genomics (TXG), Harvard Bioscience (HBIO), Thermo Fisher Scientific (TMO), Agilent Technologies (A), Mettler-Toledo International (MTD), Waters (WAT), Illumina (ILMN), Bio-Techne (TECH), Charles River Laboratories International (CRL), and Bio-Rad Laboratories (BIO). Pacific Biosciences of California vs. Its Competitors 10x Genomics Harvard Bioscience Thermo Fisher Scientific Agilent Technologies Mettler-Toledo International Waters Illumina Bio-Techne Charles River Laboratories International Bio-Rad Laboratories Pacific Biosciences of California (NASDAQ:PACB) and 10x Genomics (NASDAQ:TXG) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, dividends, analyst recommendations, institutional ownership, valuation, risk, earnings and media sentiment. Is PACB or TXG more profitable? 10x Genomics has a net margin of -25.14% compared to Pacific Biosciences of California's net margin of -430.93%. 10x Genomics' return on equity of -23.22% beat Pacific Biosciences of California's return on equity.Company Net Margins Return on Equity Return on Assets Pacific Biosciences of California-430.93% -52.07% -15.82% 10x Genomics -25.14%-23.22%-18.02% Does the media prefer PACB or TXG? In the previous week, Pacific Biosciences of California had 3 more articles in the media than 10x Genomics. MarketBeat recorded 6 mentions for Pacific Biosciences of California and 3 mentions for 10x Genomics. 10x Genomics' average media sentiment score of 1.39 beat Pacific Biosciences of California's score of 0.63 indicating that 10x Genomics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pacific Biosciences of California 1 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive 10x Genomics 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk & volatility, PACB or TXG? Pacific Biosciences of California has a beta of 2.16, meaning that its share price is 116% more volatile than the S&P 500. Comparatively, 10x Genomics has a beta of 2.03, meaning that its share price is 103% more volatile than the S&P 500. Which has better valuation and earnings, PACB or TXG? 10x Genomics has higher revenue and earnings than Pacific Biosciences of California. 10x Genomics is trading at a lower price-to-earnings ratio than Pacific Biosciences of California, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPacific Biosciences of California$154.01M3.08-$309.85M-$2.79-0.5710x Genomics$610.78M2.62-$182.63M-$1.30-10.01 Do analysts prefer PACB or TXG? Pacific Biosciences of California presently has a consensus target price of $2.06, indicating a potential upside of 30.45%. 10x Genomics has a consensus target price of $14.96, indicating a potential upside of 15.00%. Given Pacific Biosciences of California's stronger consensus rating and higher probable upside, equities research analysts plainly believe Pacific Biosciences of California is more favorable than 10x Genomics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Pacific Biosciences of California 0 Sell rating(s) 5 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.4410x Genomics 1 Sell rating(s) 6 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.43 Do insiders and institutionals believe in PACB or TXG? 84.7% of 10x Genomics shares are held by institutional investors. 2.4% of Pacific Biosciences of California shares are held by company insiders. Comparatively, 10.0% of 10x Genomics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Summary10x Genomics beats Pacific Biosciences of California on 9 of the 16 factors compared between the two stocks. Get Pacific Biosciences of California News Delivered to You Automatically Sign up to receive the latest news and ratings for PACB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PACB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PACB vs. The Competition Export to ExcelMetricPacific Biosciences of CaliforniaMED INSTRUMENTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$480.14M$6.86B$5.56B$9.05BDividend YieldN/A1.21%5.24%3.99%P/E Ratio-0.5726.6327.6520.23Price / Sales3.0899.70419.56119.26Price / CashN/A21.4826.2128.59Price / Book0.854.748.035.65Net Income-$309.85M$173.18M$3.18B$249.15M7 Day Performance22.48%1.33%2.93%3.28%1 Month Performance38.60%-1.67%1.72%3.95%1 Year Performance20.61%25.08%34.39%20.98% Pacific Biosciences of California Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PACBPacific Biosciences of California2.2928 of 5 stars$1.58+6.0%$2.06+30.5%+20.6%$474.13M$154.01M-0.57730Gap DownTXG10x Genomics4.7222 of 5 stars$11.58-1.3%$14.96+29.2%-30.5%$1.43B$610.78M-8.911,240Positive NewsHBIOHarvard Bioscience4.1065 of 5 stars$0.44-4.3%$3.00+576.0%-83.6%$19.62M$94.14M-0.34490Trending NewsTMOThermo Fisher Scientific4.9938 of 5 stars$405.83-0.6%$604.05+48.8%-20.7%$153.20B$42.88B23.80125,000News CoveragePositive NewsAAgilent Technologies4.7454 of 5 stars$118.06-0.9%$140.92+19.4%-4.1%$33.54B$6.51B29.1518,100News CoveragePositive NewsEx-DividendInsider TradeMTDMettler-Toledo International4.2809 of 5 stars$1,175.56-0.8%$1,300.36+10.6%-10.2%$24.43B$3.87B29.3218,000Positive NewsWATWaters4.553 of 5 stars$349.93-0.7%$388.00+10.9%+22.4%$20.82B$2.96B31.758,200Trending NewsAnalyst UpgradeILMNIllumina4.8734 of 5 stars$95.41+0.7%$127.39+33.5%-7.4%$15.10B$4.37B-15.729,030Positive NewsTECHBio-Techne4.9761 of 5 stars$51.45-0.8%$72.00+39.9%-25.6%$8.07B$1.16B62.743,100Positive NewsCRLCharles River Laboratories International4.0649 of 5 stars$151.64+1.1%$171.85+13.3%-21.3%$7.45B$4.05B-233.2920,100Analyst DowngradeBIOBio-Rad Laboratories4.8644 of 5 stars$241.65-1.0%$324.25+34.2%-9.2%$6.58B$2.57B-3.177,700Positive NewsAnalyst Upgrade Related Companies and Tools Related Companies TXG Competitors HBIO Competitors TMO Competitors A Competitors MTD Competitors WAT Competitors ILMN Competitors TECH Competitors CRL Competitors BIO Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PACB) was last updated on 7/7/2025 by MarketBeat.com Staff From Our PartnersThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pacific Biosciences of California, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pacific Biosciences of California With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
